<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705080</url>
  </required_header>
  <id_info>
    <org_study_id>1201</org_study_id>
    <nct_id>NCT01705080</nct_id>
  </id_info>
  <brief_title>IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN</brief_title>
  <acronym>EnligHTN-II</acronym>
  <official_title>IntErnational Non-randomized, Single-arm, Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post market clinical investigation is to further evaluate the safety and
      performance of the EnligHTN™ Renal Denervation System in the treatment of patients with
      uncontrolled hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post market, prospective, multicenter, non-randomized, single arm study of the
      EnligHTN™ Renal Denervation System. Approximately 500 subjects with uncontrolled hypertension
      will undergo renal artery ablation at approximately 40 investigational sites located
      internationally and will be followed up to five (5) years post procedure.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Abbott made a decision to not further develop the RDN program.
  </why_stopped>
  <start_date type="Actual">January 17, 2013</start_date>
  <completion_date type="Actual">November 27, 2019</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Office Systolic Blood Pressure at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Peri-procedural Events 30 Days Post-procedure</measure>
    <time_frame>30 days post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Renovascular Safety as Measured by New Renal Artery Stenosis or Aneurysm at the Site of Ablation</measure>
    <time_frame>6 months, 2 years and 5 years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 24 Months</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Office Systolic Blood Pressure &lt; 140 mmHg at 6 Months</measure>
    <time_frame>6 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Diastolic Blood Pressure at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Diastolic Blood Pressure at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Diastolic Blood Pressure at 24 Months</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Diastolic Blood Pressure at 36 Months</measure>
    <time_frame>Baseline and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Diastolic Blood Pressure at 48 Months</measure>
    <time_frame>Baseline and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Systolic Blood Pressure at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Systolic Blood Pressure at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Systolic Blood Pressure at 24 Months</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Systolic Blood Pressure at 36 Months</measure>
    <time_frame>Baseline and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Ambulatory Systolic Blood Pressure at 48 Months</measure>
    <time_frame>Baseline and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Diastolic Blood Pressure at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Diastolic Blood Pressure at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Diastolic Blood Pressure at 24 Months</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Diastolic Blood Pressure at 36 Months</measure>
    <time_frame>Baseline and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Diastolic Blood Pressure at 48 Months</measure>
    <time_frame>Baseline and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Systolic Blood Pressure at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Systolic Blood Pressure at 24 Months</measure>
    <time_frame>Baseline and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Systolic Blood Pressure at 36 Months</measure>
    <time_frame>Baseline and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Office Systolic Blood Pressure at 48 Months</measure>
    <time_frame>Baseline and 48 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">354</enrollment>
  <condition>Hypertension</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>A - EnligHTN for Severe Resistant HTN</arm_group_label>
    <description>Office systolic Blood Pressure ≥160 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - EnligHTN for Resistant HTN</arm_group_label>
    <description>Office systolic Blood Pressure ≥140 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - EnligHTN for Resistant HTN &amp; CKD</arm_group_label>
    <description>Office systolic Blood Pressure ≥140 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EnligHTN</intervention_name>
    <description>Renal artery ablation with EnligHTN system used for all groups</description>
    <arm_group_label>A - EnligHTN for Severe Resistant HTN</arm_group_label>
    <arm_group_label>B - EnligHTN for Resistant HTN</arm_group_label>
    <arm_group_label>C - EnligHTN for Resistant HTN &amp; CKD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with uncontrolled hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 18 years of age at time of consent

          -  Subject must be able and willing to provide written informed consent

          -  Subject must be able and willing to comply with the required follow-up schedule

          -  Subject has office Systolic Blood Pressure ≥ 140 mmHg at confirmatory visit

          -  Subject has a daytime mean Systolic Ambulatory Blood Pressure &gt; 135 mmHg within 90
             days prior to procedure

          -  Subject has established hypertension (diagnosed ≥12 month prior to baseline) and on a
             guideline based drug regimen at a stable and fully tolerated dose consisting of ≥ 3
             anti-hypertensive medications (including 1 diuretic) or subject has a documented drug
             intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB,
             Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3
             anti-hypertensive drugs.

        Exclusion Criteria:

          -  Subject has significant renovascular abnormalities such as renal artery stenosis &gt; 30%

          -  Subject has undergone prior renal angioplasty, renal denervation, indwelling renal
             stents, and/or abdominal aortic stent grafts

          -  Subject has hemodynamically significant valvular heart disease as determined by study
             investigator

          -  Subject has a life expectancy less than 12 months, as determined by the Investigator

          -  Subject is participating in another clinical study which has the potential to impact
             their hypertension management (pharmaceutical/device/homeopathic)

          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate
             contraceptive methods

          -  Subject has active systemic infection

          -  Subject has renal arteries with diameter(s) &lt; 4 mm in diameter

          -  Subject has an estimated GFR &lt;15 mL/min per 1.73 m2 using the Modification of Diet in
             Renal Disease (MDRD) formula

          -  Subject had a renal transplant or is awaiting a renal transplant

          -  Subject has blood clotting abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melvin Lobo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIHR Barts Cardiovascular Biomedical Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Worthley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Adelaide Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck Universitatsklinik fur Innere Medizin IV, Nephrologie und Hypertensiologie</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Cardio. Paris-Sud-Institut Jacques Cartier</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St. Etienne</name>
      <address>
        <city>St. Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil - Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabeteszentrum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bad Krozingen Herzzentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jüdisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinischen Einrichtungen der Universitat Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatskliniken des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni-Klinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University of Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Fondazione Monzino</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele/Monasterio - Stabilimento Ospedaliero di Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis Locatie Leyenburg</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Public Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donsostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Basque</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern General</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <results_first_submitted>December 21, 2017</results_first_submitted>
  <results_first_submitted_qc>December 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Denervation</keyword>
  <keyword>Renal artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT01705080/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A - EnligHTN for Severe Resistant HTN</title>
          <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="P2">
          <title>B - EnligHTN for Resistant HTN</title>
          <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="P3">
          <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
          <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="P4">
          <title>Unassigned</title>
          <description>Enrolled Participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Procedure</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1 Month</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="97"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure Post Consent</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed Procedure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed 6 Month Visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All consented subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>A - EnligHTN for Severe Resistant HTN</title>
          <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="B2">
          <title>B - EnligHTN for Resistant HTN</title>
          <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="B3">
          <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
          <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="B4">
          <title>Unassigned</title>
          <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1) eGFR value missing (n=3) Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="157"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="10.4"/>
                    <measurement group_id="B2" value="58.4" spread="11.4"/>
                    <measurement group_id="B3" value="68.4" spread="7.7"/>
                    <measurement group_id="B4" value="60.4" spread="14.0"/>
                    <measurement group_id="B5" value="61.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial Infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial Fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <units>ml/min per 1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.9" spread="20.4"/>
                    <measurement group_id="B2" value="78.5" spread="18.6"/>
                    <measurement group_id="B3" value="34.4" spread="8.6"/>
                    <measurement group_id="B4" value="67.1" spread="12.0"/>
                    <measurement group_id="B5" value="74.4" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Office Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179.8" spread="21.6"/>
                    <measurement group_id="B2" value="160.5" spread="91.0"/>
                    <measurement group_id="B3" value="176.4" spread="21.2"/>
                    <measurement group_id="B4" value="166.2" spread="24.8"/>
                    <measurement group_id="B5" value="171.5" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.0" spread="16.4"/>
                    <measurement group_id="B2" value="91.0" spread="13.0"/>
                    <measurement group_id="B3" value="90.2" spread="12.4"/>
                    <measurement group_id="B4" value="92.2" spread="18.1"/>
                    <measurement group_id="B5" value="93.8" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-hour ambulatory blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158.8" spread="16.3"/>
                    <measurement group_id="B2" value="146.7" spread="12.4"/>
                    <measurement group_id="B3" value="160.6" spread="18.6"/>
                    <measurement group_id="B4" value="150.1" spread="22.0"/>
                    <measurement group_id="B5" value="153.9" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="32"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.8" spread="13.3"/>
                    <measurement group_id="B2" value="87.2" spread="13.6"/>
                    <measurement group_id="B3" value="83.4" spread="14.7"/>
                    <measurement group_id="B4" value="84.8" spread="15.6"/>
                    <measurement group_id="B5" value="87.3" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Office Systolic Blood Pressure at 6 Months</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Systolic Blood Pressure at 6 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="26.5"/>
                    <measurement group_id="O2" value="-12.9" spread="21.7"/>
                    <measurement group_id="O3" value="-18.3" spread="25.8"/>
                    <measurement group_id="O4" value="-13.6" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Peri-procedural Events 30 Days Post-procedure</title>
        <time_frame>30 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Peri-procedural Events 30 Days Post-procedure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal Renal Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angina Pectoris</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aortic Dissection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bacterial Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calf Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest Tightness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delivery System Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device Malposition or Malfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney Pain/Flank Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Back Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Twitch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Artery Dissection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus Bradycardia (SB)/SB(Cardiac Arrhythmia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Access Site Complication (VASC) Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASC Bruise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASC Drainage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASC Hematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASC Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASC Pseudonaneurysm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASC Vessel Perforation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaso Vagal Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasospasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Renovascular Safety as Measured by New Renal Artery Stenosis or Aneurysm at the Site of Ablation</title>
        <time_frame>6 months, 2 years and 5 years post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Renovascular Safety as Measured by New Renal Artery Stenosis or Aneurysm at the Site of Ablation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New Renal Artery Stenosis at 0-6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Renal Artery Stenosis at 0-2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Renal Artery Stenosis at 0-5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 6 Months</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 6 Months</title>
          <units>mL/min per 1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="14.4"/>
                    <measurement group_id="O2" value="1.1" spread="13.5"/>
                    <measurement group_id="O3" value="5.9" spread="11.6"/>
                    <measurement group_id="O4" value="-5.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 12 Months</title>
          <units>mL/min per 1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="15.3"/>
                    <measurement group_id="O2" value="1" spread="13.1"/>
                    <measurement group_id="O3" value="3.4" spread="12.2"/>
                    <measurement group_id="O4" value="0.7" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 24 Months</title>
        <time_frame>Baseline and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Change Based on eGFR (Estimated Glomerular Filtration Rate) at 24 Months</title>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="15.5"/>
                    <measurement group_id="O2" value="-1.8" spread="15.0"/>
                    <measurement group_id="O3" value="4.8" spread="13.2"/>
                    <measurement group_id="O4" value="6.4" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Office Systolic Blood Pressure &lt; 140 mmHg at 6 Months</title>
        <time_frame>6 months post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Office Systolic Blood Pressure &lt; 140 mmHg at 6 Months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Diastolic Blood Pressure at 6 Months</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Diastolic Blood Pressure at 6 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="9.3"/>
                    <measurement group_id="O2" value="-4" spread="13.4"/>
                    <measurement group_id="O3" value="-5.1" spread="13.1"/>
                    <measurement group_id="O4" value="-8.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Diastolic Blood Pressure at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Diastolic Blood Pressure at 12 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="10.3"/>
                    <measurement group_id="O2" value="-4.3" spread="13.4"/>
                    <measurement group_id="O3" value="-7.6" spread="14.1"/>
                    <measurement group_id="O4" value="-8" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Diastolic Blood Pressure at 24 Months</title>
        <time_frame>Baseline and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Diastolic Blood Pressure at 24 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="10.4"/>
                    <measurement group_id="O2" value="-5.2" spread="12.7"/>
                    <measurement group_id="O3" value="-7.6" spread="10.8"/>
                    <measurement group_id="O4" value="-5.5" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Diastolic Blood Pressure at 36 Months</title>
        <time_frame>Baseline and 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Diastolic Blood Pressure at 36 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="12.8"/>
                    <measurement group_id="O2" value="-8.1" spread="16.6"/>
                    <measurement group_id="O3" value="-8.1" spread="10.6"/>
                    <measurement group_id="O4" value="-2" spread="NA">Only 1 participant analyzed in Unassigned group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Diastolic Blood Pressure at 48 Months</title>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Data were not collected for participants in Group C and Unassigned Group at 48 months.</population>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Diastolic Blood Pressure at 48 Months</title>
          <population>Data were not collected for participants in Group C and Unassigned Group at 48 months.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="5.0"/>
                    <measurement group_id="O2" value="-19" spread="NA">Only 1 participant analyzed in Group B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Systolic Blood Pressure at 6 Months</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Systolic Blood Pressure at 6 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="16.4"/>
                    <measurement group_id="O2" value="-4.4" spread="17.1"/>
                    <measurement group_id="O3" value="-8.1" spread="24.6"/>
                    <measurement group_id="O4" value="-16.6" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Systolic Blood Pressure at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Systolic Blood Pressure at 12 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="18.1"/>
                    <measurement group_id="O2" value="-5.1" spread="16.8"/>
                    <measurement group_id="O3" value="-15.8" spread="24.3"/>
                    <measurement group_id="O4" value="-12.6" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Systolic Blood Pressure at 24 Months</title>
        <time_frame>Baseline and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Systolic Blood Pressure at 24 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="18.6"/>
                    <measurement group_id="O2" value="-7.5" spread="16.2"/>
                    <measurement group_id="O3" value="-15.9" spread="18.7"/>
                    <measurement group_id="O4" value="-9.8" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Systolic Blood Pressure at 36 Months</title>
        <time_frame>Baseline and 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Systolic Blood Pressure at 36 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" spread="19.8"/>
                    <measurement group_id="O2" value="-8.1" spread="17.1"/>
                    <measurement group_id="O3" value="-13.4" spread="20.8"/>
                    <measurement group_id="O4" value="-7" spread="NA">Only 1 participant analyzed in Unassigned group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Ambulatory Systolic Blood Pressure at 48 Months</title>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Data were not collected for participants in Group C and Unassigned Group at 48 months.</population>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Ambulatory Systolic Blood Pressure at 48 Months</title>
          <population>Data were not collected for participants in Group C and Unassigned Group at 48 months.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="2.9"/>
                    <measurement group_id="O2" value="-51" spread="NA">Only 1 participant analyzed for Group B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Diastolic Blood Pressure at 6 Months</title>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Diastolic Blood Pressure at 6 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="13.7"/>
                    <measurement group_id="O2" value="-5.3" spread="12.2"/>
                    <measurement group_id="O3" value="-13.1" spread="10.1"/>
                    <measurement group_id="O4" value="-7.2" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Diastolic Blood Pressure at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Diastolic Blood Pressure at 12 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="14.9"/>
                    <measurement group_id="O2" value="-5.7" spread="13.3"/>
                    <measurement group_id="O3" value="-13" spread="13.3"/>
                    <measurement group_id="O4" value="-8.9" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Diastolic Blood Pressure at 24 Months</title>
        <time_frame>Baseline and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Diastolic Blood Pressure at 24 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="16.3"/>
                    <measurement group_id="O2" value="-8.3" spread="11.7"/>
                    <measurement group_id="O3" value="-16" spread="14.8"/>
                    <measurement group_id="O4" value="-1.4" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Diastolic Blood Pressure at 36 Months</title>
        <time_frame>Baseline and 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Diastolic Blood Pressure at 36 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="17.0"/>
                    <measurement group_id="O2" value="-9.9" spread="12.3"/>
                    <measurement group_id="O3" value="-13.2" spread="12.1"/>
                    <measurement group_id="O4" value="1" spread="NA">Only 1 participant analyzed in Unassigned group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Diastolic Blood Pressure at 48 Months</title>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Data were not collected for participants in Unassigned group at 48 months.</population>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Diastolic Blood Pressure at 48 Months</title>
          <population>Data were not collected for participants in Unassigned group at 48 months.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="15.8"/>
                    <measurement group_id="O2" value="-15.5" spread="3.5"/>
                    <measurement group_id="O3" value="-22" spread="NA">Only 1 participant analyzed in Group C</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Systolic Blood Pressure at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Systolic Blood Pressure at 12 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="27.0"/>
                    <measurement group_id="O2" value="-12.5" spread="22.6"/>
                    <measurement group_id="O3" value="-17" spread="28.7"/>
                    <measurement group_id="O4" value="-19.9" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Systolic Blood Pressure at 24 Months</title>
        <time_frame>Baseline and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Systolic Blood Pressure at 24 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.6" spread="28.9"/>
                    <measurement group_id="O2" value="-14.7" spread="20.7"/>
                    <measurement group_id="O3" value="-24" spread="28.0"/>
                    <measurement group_id="O4" value="-2.1" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Systolic Blood Pressure at 36 Months</title>
        <time_frame>Baseline and 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Systolic Blood Pressure at 36 Months</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" spread="30.9"/>
                    <measurement group_id="O2" value="-15.9" spread="26.5"/>
                    <measurement group_id="O3" value="-30.2" spread="22.5"/>
                    <measurement group_id="O4" value="5" spread="NA">Only 1 participant analyzed in Unassigned group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Office Systolic Blood Pressure at 48 Months</title>
        <time_frame>Baseline and 48 months</time_frame>
        <population>Data were not collected for participants in Unassigned Group at 48 months.</population>
        <group_list>
          <group group_id="O1">
            <title>A - EnligHTN for Severe Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥160 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O2">
            <title>B - EnligHTN for Resistant HTN</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O3">
            <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
            <description>Office systolic Blood Pressure ≥140 mmHg
Participant is taking ≥3 anti-hypertensive medications (including 1 diuretic), or participant has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Participant has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
          </group>
          <group group_id="O4">
            <title>Unassigned</title>
            <description>Enrolled participants missing baseline data required for grouping.
The following baseline data was missing in 10 participants that underwent procedure:
Inclusion criteria 6 not Yes (n=1)
eGFR value missing (n=3)
Office Systolic Blood Pressure &lt;140mmHg (n=6)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Office Systolic Blood Pressure at 48 Months</title>
          <population>Data were not collected for participants in Unassigned Group at 48 months.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="26.2"/>
                    <measurement group_id="O2" value="-30.5" spread="12.0"/>
                    <measurement group_id="O3" value="-38" spread="NA">Only 1 participant analyzed in Group C.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of renal denervation procedure (vascular access) through all available follow up (up to 5 years)</time_frame>
      <desc>Per protocol, only serious or related events were collected. Some serious events, including deaths, may not be related to the study device.</desc>
      <group_list>
        <group group_id="E1">
          <title>A - EnligHTN for Severe Resistant HTN</title>
          <description>Office systolic Blood Pressure ≥160 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="E2">
          <title>B - EnligHTN for Resistant HTN</title>
          <description>Office systolic Blood Pressure ≥140 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="E3">
          <title>C - EnligHTN for Resistant HTN &amp; CKD</title>
          <description>Office systolic Blood Pressure ≥140 mmHg
Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated ≥15 GFR &lt;45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula
EnligHTN: Renal artery ablation with EnligHTN system used for all groups</description>
        </group>
        <group group_id="E4">
          <title>Unassigned</title>
          <description>Enrolled subjects missing baseline data required for grouping.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paroxysmal Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ST Segment Changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Superior Vena Cava (SVC) Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Unstable Angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Perforated Appendix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bacterial Infections of the Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Allergic Dye Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Calf Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Subdural Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seizure/Convulsions/Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack (TIA)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Pain/Flank Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Common Cold/Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Hypertension/Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Carotid Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Artery Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renovascular Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vascular access-site complication (VASC) Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASC Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASC Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia/Sinus Bradycardia (Cardiac Arrhythmia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASC Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Low Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle Twitch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Malposition or Malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Renal Function</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Kidney Pain/Flank Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other - Small wedge shaped abnormalities in both kidneys in keeping with small infarcts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASC Bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASC Bruise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASC Drainage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASC Hematoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASC Vessel Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaso Vagal Response</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="149"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Madej</name_or_title>
      <organization>Abbott</organization>
      <phone>651-756-2230</phone>
      <email>smadej@sjm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

